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Evidence for Existence in Human Tissuesof
Monomersfor Plasticsand Rubber Manufacture
by Mary S.Wolff*
Although exposure to many industrially important monomers is controlled by law,
few of these reactive chemicals have been determined in human tissues. Analogy with
other fat-soluble organic substances strongly implies that these monomers may be
retained in tissue, suhject to the usual physiological constraints of metabolism, solu-
bility and volatility. The storage of DDT and PCBs is discussed, as well as tetrachloro-
ethylene (PCE) and trichloroethylene (TCE), which are chemically similar to many
industrially used monomers. Styrene in blood and breath and its metabolites in urine
have been studied in humans. Styrene and vinyl chloride have been measured in fat
tissue of polymerization workers.
Evidence for the presence of monomers and
other unmetabolized organic materials in hu-
mans is surprisingly scarce, in spite of expo-
sures to a large number of substances in the
environment that are very fat soluble, and
therefore prime candidates for prolonged body
residence.
Recent epidemiological and clinical field
studies have been conducted by this laboratory
among workers exposed to organic materials,
including polymerization workers, anesthesiolo-
gists and workers making capacitors and trans-
formers (PCB workers), and our interest has
been directed toward the study of the storage
and turnover in blood and adipose tissue of
fat-soluble organic compounds.
The distributional dynamics of many such
compounds in the body can be derived using
the compartmental model, with which anesthe-
siologists have studied uptake and elimination
of anesthetics. Thus, during acute exposures
(in anesthesia amounting to 1-2% of a halo-
genated anesthetic in breathing air) the blood-
vessel rich organs and tissues are rapidly sat-
urated due to high blood flow and medium solu-
bility, while fat tissues are slowly saturated,
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having a high capacity and low blood flow. Fat
tissues comprise about 20%S of the normal
body weight (1). The converse pathway is
followed during elimination from tissues of a
halogenated anesthetic, or any nonpolar or-
ganic material, but this is affected by three
factors: fat solubility (more soluble, more
slowly eliminated) ; volatility (more volatile,
more easily expired); and metabolism (more
readily metabolized, more quickly excreted).
The variability of the latter route is affected
by many factors, including enzymatic activity
(determined in part by heredity and by dietary,
drinking and smoking habits) and the chemi-
cal nature of the substance (nitrous oxide and
cyclopropane are 97% and 99% expired un-
changed (2), while styrene is 95% metabolized
(3).
Anesthesiologists have further contributed
to our knowledge of body retention of halo-
genated hydrocarbons by extensive studies of
blood and breath levels of anesthetic agents in
operating room personnel. Fat-soluble anes-
thetics are typically detectable in breath for a
day or so following exposures (usually less
than 100 ppm exposure and 1-10 ppm in ex-
pired air) indicating tissue retention, which
has been presumed, but not demonstrated, to
occur in the fat depot (4, 5).
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humans are limited to pesticides and PCBs.
DDT is perhaps the most extensively studied
material in humans and animals and is a sub-
stance which defies all normal excretory at-
tempts: it is nonvolatile, very lipid soluble and
very difficult to metabolize. In the occupational
setting, a relationship between exposure level
and fat level of DDT has been observed, with
300-600 ppm found in adipose tissue of work-
ers (6, 7). The health implications of DDT
retention are not established, although Poland
et al. demonstrated, among workers with high
fat and blood DDT, an elevated, but not li-
nearly correlated, enzymatic capacity for
phenylbutazone (6). In animals a threshold of
DDT in fat (11 uLg/g) is necessary to affect
phenobarbital metabolism rate (8). An in-
gested dose of DDT is retained in human fat
tissue for as long as 3 yr, while in correspond-
ing animal tissues, elimination of similar levels
was accomplished in 0.5-1.5 yr (9). Clearly,
extrapolation from the animal to human situ-
ation is not straightforward.
PCBs are a similarly chemically inert organic
family (contributing to their industrial util-
ity), which have been detected in water, birds,
fish, and human tissues. Severe cases of symp-
tomatic PCB exposures occurred in Japanese
persons who consumed contaminated rice oil
(Yusho disease, Table 1). Levels of about 40
ppm PCB in fat tissue were observed initially
in these persons, declining over a period of
2-5 yr to that of the general population in
Japan (0.2-4 ppm) (10). PCBs have been
found at trace-2ppm levels (11) in the United
States general population (Table 2). Blood
levels of Japanese PCB workers were deter-
mined to be ca. 0.4 ppm (10). Trace amounts
(parts per billion) of polybrominated biphenyls
were observed in livestock and produce in
Michigan following a recent incident in which
a polybrominated biphenyl compound was mis-
takenly mixed into livestock feed. The result-
ing contamination forced the extermination of
thousands of livestock and hundreds of thou-
sands of chickens and eggs (12).
Tetrachloroethylene and trichloroethylene
(PCE and TCE) are important industrial solv-
ents. Their tissue turnover patterns are useful
as model studies for similar monomers such as
vinyl chloride and vinylidene chloride, for
which no human data exist. TCE, which has
been used as an inhalation anesthetic, recently
Table 1. Adipose tissue levels of PCBs in Japanese
Yusho patients.a
Time since
exposure, yr PCB level, ppm
0 40
1 3
2 0.7
4 3
7 0.2
National survey b 0.2-4
a Data of Kuratsune et al. (10).
b Males/females, 25-49 yr old.
Table 2. PCBs in adipose tissues of U.S. general
population.a
% of total cases
PCB level, ppm (N = 688)
0 34
Trace-1 33
1-2 27
>2 5
aData of Yobs (11).
has been found to be carcinogenic in mice at
high levels of oral administration (13).
PCE is readily absorbed during inhalation
by humans and very slowly excreted. After
exposure at 100 ppm (the present TLV), for
7 hr on each of 5 successive days, PCE was
detected in the breath at levels of about 1 ppm
14 days later. The expirational half-life was 3
days. Exposure for only 1 day produced a simi-
lar half-life, with 1 ppm in breath reached at
5 days (14).
TCE in breath of humans is detectable (ca 1
ppm) for at least 4 days after exposure to
100-200 ppm (TLV 100 ppm), 7 hr/day for 5
days, with a half-life of 1 day (15). As with
PCE, persistence in breath is accentuated
among persons exposed for the longest times.
Breath levels of persons exposed once to 100-
200 ppm for 1-4 hr were reduced to 1 ppm
within 2 days (15). The metabolic half-life of
PCE and TCE are about twice as long as that
in breath, 144 and 41 hr, respectively, for uri-
nary metabolites (16). These half-lives are
many times longer than similar determinations
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xylene, styrene, and phenol (16, 17).
Vinyl chloride (VC) exposure has been asso-
ciated with excess cancer incidence among
vinyl chloride-exposed workers, and in animals
(18). In laboratory animals most of the VC
absorbed during inhalation was metabolized.
Of a radiolabeled dose, only 0.02% was de-
tected as expired monomer, with 98% of the
dose recovered. A small amount of radioactivity
was retained after 75 hr, mainly in the liver
(19).
VC has been detected in the subcutaneous
fat of polymerization workers (Table 3). In
spite of its volatility and its facile metabolism
by rats, the lipophilicity of VC appears to
allow fat retention in humans (20).
Table 3. Presence of vinyl chloride in fat of
polymerization workers.a
VCM in subcutaneous fat,
Exposure estimate b (No. samples/
Intensity Most recent no. samples analyzed)
L-M Present 5/7
H Present 2/4
L-M 3 months 1/2
H, long 3 months 6/8
H, < 1 yr 3 months 0/2
H, long 1-12 yrs. 5/5
None 0/1
Total 19/29
a Data of Knittle et al. (20).
b Exposure intensity estimated as
to medium (L-M).
heavy (H) or light
Human uptake and metabolism of styrene
has been fairly well studied. Styrene can be
absorbed by inhalation or skin contact. During
exposure to 20-100 ppm, about 60% of the
styrene inhaled is absorbed by the body (3,
21). Of this amount, metabolism to mandelic
acid (85%c) and phenylglycolic acid (10%)
accounts for most of the absorbed styrene (3).
Metabolism to hippuric acid and conjugates of
phenylglycol also occurs (17). Exhalation ac-
counts for about 1% of the styrene absorbed
(22, 23).
Styrene is very soluble in blood and fat,
more so than many halogenated hydrocarbons.
Following exposure at 100 ppm, blood levels
of 0.2-15 ppm styrene have been determined
(22, 23). As with PCE and TCE, blood and
breath levels are proportional to the intensity
and not duration, of exposure. Persistence in
breath is related to duration of exposure. Thus,
after 2 and 7 hr exposure to 100 ppm styrene,
breath levels decrease from 2-3 ppm to 0.05
and 0.5 ppm, respectively over a period of 6
hr (23). Exertion during exposure to styrene
changes blood, but not breath, concentrations.
During exposure to 150 ppm styrene, blood
levels varied with exercise from 2 ppm (at
rest), to 6 ppm (50-watt exercise), to 16 ppm
(150-watt exercise) (22).
The urinary half-life of styrene metabolites
is about 8 hr, with detectable levels continuing
for 30 hr (17). (The breath half-life of styrene
is 1-3 hr, with detectable levels persisting as
long as 20 hr (ca. 0.1 ppm) (23).
Table 4. Styrene and ethylbenzene in subcutaneous fat
of styrene polymerization workers.a
Styrene Ethyl-
Estimated Time since concentra- benzene in
exposure b last exposure tion, ppm C fat, ppm e
H 0 0.2 0.1
M 0 0.2 0.1
H 4 hr 0.3 0.4
M 8 1.0 0.7
M 2 days - 0.1
H 2 0.4 0.7
H 2.5 0.2 0.2
H 2.5 0.1 0.1
H 3 0.2 0.2
L 3 0.2
M 4 0.1
M 14
H 90 0.2
C6H6
CF3CHBrCl
a Data of Wolff et al. (unpublished, work in progress).
b Exposures estimated as H (heavy), M (medium),
L (light).
,Limit of detection in 10 mg fat sample, 0.2 ppm
styrene, 0.1 ppm ethylbenzene by gas chromatography.
We have measured styrene and ethyl ben-
zene in the subcutaneous fat of workers and
found levels of 0.2-1 ppm, roughly related to
the degree of exposure and time since last ex-
posure (Table 4). The blood levels of these
workers have been measured separately and
are in the 0-10 ppb range (J. Eisinger and W.
Blumberg, work in progress.).
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than 48 hr following the last exposure, longer
than detectability in breath of experimental
subjects after sustained exposure at 100 ppm
(23). This finding is of interest, since styrene
is a monomer more readily metabolized than
the halogenated hydrocarbons.
Several recent studies suggest important
areas for future investigations. Exposure to
dichloromethane has recently been correlated
to high carboxyhemoglobenemia (24). The per-
sistence of bromine in rat tissue for 24 hr
following exposure to brominated fire retard-
ants has been reported at this conference. The
demonstration by Montesano of marked muta-
genic assay activity by chloroprene (25)
(greater than for vinyl chloride) should stim-
ulate study of this monomer in human and
animal tissue. Its nonchlorinated analog, buta-
diene, has a very rapid turnover in animal
tissues following very high exposures, similar
to that of styrene under the same conditions
(26).
Another important industrial monomer
which has not been adequately studied is
acrylamide, a potent
mg/mi3). It has been
neurotoxin (TLV 0.3
measured in urine of
polymerization workers, although no published
data exist (27). Exposure of acrylamide, a
solid (mp 850C) vinyl amide, can occur via
dust inhalation or dermal contact. Up to 2%
monomer can be retained in the polymer. Its
cumulative neurotoxicity has a demonstrated
threshold in animals, and the biological half-
life in animals is 24 hr. Most of a radioactive
dose in animals appears to be bound to blood
and tissue protein, persisting in significant
amounts for more than 14 days (27).
Table 5 summarizes some of the reported
findings of industrial chemicals in blood and
fat. Table 6 summarizes some available turn-
over data for fat-soluble industrial chemicals.
Table 5. Levels of industrial chemicals in blood and fat
of workers.
Concentration, ppm
Chemical Blood Fat Reference
DDT 1.4 310 (6) a
PCBs 0.4 40 (10)
(Yusho)
Styrene 0.2-3 ca. 1 (23)
Vinyl chloride ca. 1 (20)
a Control: 0.05 ppm (blood), 2 ppm (fat).
Table 6. Respiratory and urinary excretion of some industrial compounds.
Half-life, hr Breath
Compound TLV,ppm (mg/m3) Respiratory Urinary detectability Reference
Acrylamide
CH2=CHCO2NH2 (0.3) 24 (14C)a (27)
Butadiene
CH2=CH-CH=CH2 1000 (2200) Rapid (26)
Styrene
CGHa-CH=CH2 100 (420) 0.5-3 8 20hr (16,17,23)
Ethylbenzene
C8Hs-CH2CH3 100 (435) Styrene 8 (3,26)
Phenylacetylene
CHs-C=CH 24a 24a (28)
Toluene 100 (375) 7 (16)
C,H-CH3
Xylene 100 (435) 7 (16)
CHC6H4CH3
Trichloroethylene 100 (535) 25 41 40-100 hr (15,16)
ClCH=CC12
Tetrachloroethylene 100 (760) 65 144 14 days (14,16)
Cl2C=CCl s
a In animals.
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